Clinical Research Details

Back to List
Descriptive Information
Phase II pilot study to estimate the adverse events associated with the lock solution when used to salvage central line associated bloodstream infection (CLABSI)

Souha Kanj
sk11@aub.edu.lb

IM.SK.10
Completed

Clinical Research - Clinical Trials (phase 0, 1,2 3 & 4)  

Phase 2  

No
Collaborators
  • R. Hachem A.
  • Chaftari A.
  • Hamal K.
  • Garoge M.
  • Jordan P.
  • Deshmukh M.
  • Alshuaibi J
  • Rosenblatt N
  • Hamerschlak A.
  • Sherif S.
  • Kanj I.
  • Raad
Sponsors
  • MD Anderson
Coordinators
Saeed El Zein
se82@aub.edu.lb
Extension: 2093
Conditions and Keywords
Central Line Associated Blood Stream Infection (CLABSI)
Lock therapy, Salvage of the line
Study Design
Treatment
Safety and/or Efficacy Study
Open Label
Parallel
Non- Randomized
Eligibility and IRB
Both
Min: 18
Max:
Yes
No




1. Age>18 years, 2. CVC in place at least 14 days. In neutropenic 2 hours differential time to positivity between central and perpheral, 3. Female non-lactating and at no risk for pregnancy, 4. For short term catheters, enroll if CVC cannot be removed.

1. allergic to tetracyclin or EDTA, 2. On disulfiram drugs, 3. Severe sepsis, hemodynamic instability, 4. Prosthetic valve, 5. Signs of deep seated infection, 6. cathter exit site infection, 7. Candida line infection, 8. Previously entered on the study.

Back to List